These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

94 related articles for article (PubMed ID: 20038828)

  • 41. Characteristics of Clinical Studies Conducted Over the Total Product Life Cycle of High-Risk Therapeutic Medical Devices Receiving FDA Premarket Approval in 2010 and 2011.
    Rathi VK; Krumholz HM; Masoudi FA; Ross JS
    JAMA; 2015 Aug; 314(6):604-12. PubMed ID: 26262798
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Medical devices; exemptions from premarket notification and reserved devices; class I--FDA. Notice.
    Fed Regist; 1998 Feb; 63(21):5387-93. PubMed ID: 10177333
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Medical devices; exemptions from premarket notification; class II devices--FDA, Final rule.
    Fed Regist; 1998 Nov; 63(212):59222-31. PubMed ID: 10187384
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Premarket clinical evaluation of novel cardiovascular devices: quality analysis of premarket clinical studies submitted to the Food and Drug Administration 2000-2007.
    Kramer DB; Mallis E; Zuckerman BD; Zimmerman BA; Maisel WH
    Am J Ther; 2010; 17(1):2-7. PubMed ID: 20038828
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Strength of study evidence examined by the FDA in premarket approval of cardiovascular devices.
    Dhruva SS; Bero LA; Redberg RF
    JAMA; 2009 Dec; 302(24):2679-85. PubMed ID: 20040556
    [TBL] [Abstract][Full Text] [Related]  

  • 46. The FDA's role in medical device clinical studies of human subjects.
    Saviola J
    J Neural Eng; 2005 Mar; 2(1):S1-4. PubMed ID: 15876645
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Pediatric cardiovascular safety: challenges in drug and device development and clinical application.
    Bates KE; Vetter VL; Li JS; Cummins S; Aguel F; Almond C; Dubin AM; Elia J; Finkle J; Hausner EA; Joseph F; Karkowsky AM; Killeen M; Lemacks J; Mathis L; McMahon AW; Pinnow E; Rodriguez I; Stockbridge NL; Stockwell M; Tassinari M; Krucoff MW
    Am Heart J; 2012 Oct; 164(4):481-92. PubMed ID: 23067905
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Clinical end points in coronary stent trials: a case for standardized definitions.
    Cutlip DE; Windecker S; Mehran R; Boam A; Cohen DJ; van Es GA; Steg PG; Morel MA; Mauri L; Vranckx P; McFadden E; Lansky A; Hamon M; Krucoff MW; Serruys PW;
    Circulation; 2007 May; 115(17):2344-51. PubMed ID: 17470709
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Safety and effectiveness considerations for clinical studies of visual prosthetic devices.
    Cohen ED
    J Neural Eng; 2007 Mar; 4(1):S124-9. PubMed ID: 17325410
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Making sense of the food and drug administration.
    Connor JA
    Semin Pediatr Surg; 2006 Nov; 15(4):293-301. PubMed ID: 17055960
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Food and Drug Administration regulation of in vitro diagnostic devices.
    Mansfield E; O'Leary TJ; Gutman SI
    J Mol Diagn; 2005 Feb; 7(1):2-7. PubMed ID: 15681468
    [TBL] [Abstract][Full Text] [Related]  

  • 52. An overview of the regulatory aspects of medical devices from the viewpoint of research and device manufacturing.
    Patrick J
    Reg Anesth; 1993; 18(6 Suppl):424-7. PubMed ID: 8110642
    [TBL] [Abstract][Full Text] [Related]  

  • 53. An overview of FDA medical device regulation as it relates to deep brain stimulation devices.
    Peña C; Bowsher K; Costello A; De Luca R; Doll S; Li K; Schroeder M; Stevens T
    IEEE Trans Neural Syst Rehabil Eng; 2007 Sep; 15(3):421-4. PubMed ID: 17894274
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Gender bias in studies for Food and Drug Administration premarket approval of cardiovascular devices.
    Dhruva SS; Bero LA; Redberg RF
    Circ Cardiovasc Qual Outcomes; 2011 Mar; 4(2):165-71. PubMed ID: 21364127
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Medical devices: US medical device regulation.
    Jarow JP; Baxley JH
    Urol Oncol; 2015 Mar; 33(3):128-32. PubMed ID: 25458071
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Current challenges for clinical trials of cardiovascular medical devices.
    Zannad F; Stough WG; Piña IL; Mehran R; Abraham WT; Anker SD; De Ferrari GM; Farb A; Geller NL; Kieval RS; Linde C; Redberg RF; Stein K; Vincent A; Woehrle H; Pocock SJ
    Int J Cardiol; 2014 Jul; 175(1):30-7. PubMed ID: 24861254
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Cardiovascular biomarkers and surrogate end points: key initiatives and clinical trial challenges.
    Heinonen TM; Aamer M; Marshall C; Black DM; Tardif JC
    Expert Rev Cardiovasc Ther; 2012 Aug; 10(8):989-94. PubMed ID: 23030288
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Missing data in the regulation of medical devices.
    Campbell G; Pennello G; Yue L
    J Biopharm Stat; 2011 Mar; 21(2):180-95. PubMed ID: 21390995
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Spinal devices in the United States-investigational device exemption trials and premarket approval of class III devices.
    Golish SR; Reed ML
    Spine J; 2017 Jan; 17(1):150-157. PubMed ID: 27737804
    [TBL] [Abstract][Full Text] [Related]  

  • 60.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.